Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

Overall survival and progression-free survival outcomes appear similar for lutetium-177 and actinium-225 in select patients with mCRPC, with some differences between radioligand therapies.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67 Cu-SAR-bisPSMA.This follows the recent ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new publication[2] of positive in vivo data, in the journal Diabetes, Metabolic Syndrome ...

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

HIGHLIGHTS The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of ...